A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel‑Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome

Trial Profile

A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel‑Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Postpoliomyelitis syndrome
  • Focus Therapeutic Use
  • Acronyms FORCE
  • Sponsors Grifols
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Sep 2020.
    • 24 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 30 Jul 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top